2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias

2025 Focused update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias - European Society of Cardiology (ESC) / European Atherosclerosis Society (EAS)

Since the publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular (CV) risk, there have been several randomized controlled trials that might change patient management ahead of the next scheduled full dyslipidaemia Guidelines. This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until 31 March 2025. All major randomized controlled clinical trials and meta-analyses published after the publication of the 2019 ESC/EAS Guidelines were presented and discussed in detail before a consensus was reached about any possible classes of recommendations (see Table 1) and levels of evidence (see Table 2) to be assigned; these were then voted upon for inclusion by all Task Force members. Members with declared conflicts of interests in specific topics were asked to abstain from voting on those topics.


Read full Guideline